0.76
-0.0007(-0.09%)
Currency In USD
| Previous Close | 0.76 |
| Open | 0.75 |
| Day High | 0.79 |
| Day Low | 0.74 |
| 52-Week High | 2.46 |
| 52-Week Low | 0.73 |
| Volume | 421,237 |
| Average Volume | 803,112 |
| Market Cap | 36.99M |
| PE | -0.93 |
| EPS | -0.81 |
| Moving Average 50 Days | 0.96 |
| Moving Average 200 Days | 1.21 |
| Change | -0 |
If you invested $1000 in PDS Biotechnology Corporation (PDSB) 10 years ago, it would be worth $2.7 as of November 23, 2025 at a share price of $0.755. Whereas If you bought $1000 worth of PDS Biotechnology Corporation (PDSB) shares 5 years ago, it would be worth $387.38 as of November 23, 2025 at a share price of $0.755.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
PDS Biotechnology Announces up to $11.1 Million Registered Direct Offering
GlobeNewswire Inc.
Nov 11, 2025 8:31 PM GMT
$5.3 million Upfront with up to an Additional $5.8 million of Aggregate Gross Proceeds upon the Cash Exercise in Full of WarrantsPRINCETON, N.J., Nov. 11, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “
PDS Biotechnology Announces Translational Data Showing Strong Immunological and Clinical Activity of PDS0101 and PDS01ADC Presented at SITC 2025
GlobeNewswire Inc.
Nov 10, 2025 1:30 PM GMT
Translational study shows that multiple immunological biomarkers predict the clinical activity of PDS0101 combination therapy PDS01ADC reprograms natural killer (NK) cells to possess characteristics that make them more active in killing cancer cellsP
PDS Biotech Announces Conference Call and Webcast for Third Quarter 2025 Financial Results
GlobeNewswire Inc.
Nov 06, 2025 1:00 PM GMT
PRINCETON, N.J., Nov. 06, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today anno